158 related articles for article (PubMed ID: 24300821)
1. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
[TBL] [Abstract][Full Text] [Related]
2. [The use of rebif in the Moscow Municipal Multiple Sclerosis Center].
Popova EV; Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):68-71. PubMed ID: 21916159
[TBL] [Abstract][Full Text] [Related]
3. [Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Popova EV; Boĭko AN; Vasil'ev AV; Davydovskaia MV; Zavalishin IA; Kotov SV; Krotenkova MV; Khachanova NV; Sharanova SN; Shchur SG; Iakushina TI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):56-61. PubMed ID: 22951783
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
5. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908
[TBL] [Abstract][Full Text] [Related]
6. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Knobler RL; Greenstein JI; Johnson KP; Lublin FD; Panitch HS; Conway K; Grant-Gorsen SV; Muldoon J; Marcus SG; Wallenberg JC
J Interferon Res; 1993 Oct; 13(5):333-40. PubMed ID: 8301153
[TBL] [Abstract][Full Text] [Related]
7. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
9. [The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
Boĭko AN; Batysheva TT; Bykova OV; Davydovskaia MV; Demina TL; Lashch NIu; Nankina IA; Ovcharov VV; Popova EV; Popova NF; Boĭko OV; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):98-103. PubMed ID: 22677685
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
11. [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].
Zimmermann C; Walther EU; Goebels N; Lienert C; Kappos L; Hartung HP; Hohlfeld R
Nervenarzt; 1999 Aug; 70(8):759-63. PubMed ID: 10483579
[TBL] [Abstract][Full Text] [Related]
12. [A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3].
Kotov SV; Kudlay DA; Lizhdvoy VY; Stashuk GA; Magomedova SB
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):107-115. PubMed ID: 31156249
[TBL] [Abstract][Full Text] [Related]
13. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
14. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
15. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study.
Tenembaum SN; Banwell B; Pohl D; Krupp LB; Boyko A; Meinel M; Lehr L; Rocak S; Cantogno EV; Moraga MS; Ghezzi A;
J Child Neurol; 2013 Jul; 28(7):849-56. PubMed ID: 23666046
[TBL] [Abstract][Full Text] [Related]
17. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
19. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
[TBL] [Abstract][Full Text] [Related]
20. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
